Agents and Actions

, Volume 6, Issue 1–3, pp 251–255 | Cite as

In vivo and in intro macrophage activation by systemic adjuvants

  • M. Bruley-Rosset
  • I. Florentin
  • G. Mathé
Symposium 4 General Aspects of Inflammation I


Six systemic adjuvants of immunity were tested for their ability to induce macrophage activation. Four of them: living BCG, hydrosoluble extracts from BCG (HIU II) and fromM. smegmatis (IPM), and lipopolysaccharide fromE. coli (LPS), when administered to normal mice render macrophages non-specifically cytotoxic for tumor cells in vitro. The intensity of this phenomenon varied according to the route and time of adjuvant administration. In contrast, lentinan extracted fromLentinus edodes, and levamisole which is a synthetic chemical compound, depressed macrophage cytotoxic potential.

BCG, IMP and LPS were shown to have a direct action on macrophages. After in vitro exposure to these agents, the cytotoxic potential of normal macrophages was greatly increased. Levaminsole was unable ot stimulate this macrophage function directly in vitro. On the other hand, such a macrophage activation has been induced in vitro when normal macrophages were cultivated in the presence of MIF coming from the supernatant of human lymphoblastoid cell lines.


Tumor Cell Chemical Compound Direct Action Normal Mouse Macrophage Activation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Black, M.M., Kerpe, S. and Speer, F.D., Am. J. Path.29, 505–522 (1953).PubMedGoogle Scholar
  2. [2]
    Gorer, P.A., Adv. Cancer Res.4, 149–186 (1958).Google Scholar
  3. [3]
    Ghershon, R.K., Carter, R.L., and Lane, N.S., Am. J. Path.51, 1111–1133 (1967).PubMedGoogle Scholar
  4. [4]
    Halpern, B.N., Biozzi, G., Stipfel, C., and Mouton, D., Nature212, 853–854 (1966).PubMedGoogle Scholar
  5. [5]
    Weatherly, N.P., J. Parasit.56, 748–756 (1970).PubMedGoogle Scholar
  6. [6]
    Hibbs, J.B., Lambert, L.H., and Remington, J.S., J. infect. Dis.124, 587–592 (1971).PubMedGoogle Scholar
  7. [7]
    Keller, R., Ogilvie, B.H., and Simpson, E., Lancet1 678–681 (1971).CrossRefPubMedGoogle Scholar
  8. [8]
    Yasphe, D.J., in:Immunological Parameters of Host-Tumor Relationships, 1 vol. (Ed. Weiss, D.W.; Academic Press, New York 1971), p. 90–107.Google Scholar
  9. [9]
    Castro, J.E., Eur. J. Cancer10, 121–127 (1974).PubMedGoogle Scholar
  10. [10]
    Hibbs, J.B., Lambert, L.H., and Remington, J.S., Nature New Biol.235, 48–50 (1972).PubMedGoogle Scholar
  11. [11]
    Alexander, P., and Evans, R., Nature New Biol.232, 76–78 (1971).PubMedGoogle Scholar
  12. [12]
    Nathan, C.F., Remold, H.G. and David, J.R., J. exp. Med.137, 275–290 (1973).CrossRefPubMedGoogle Scholar
  13. [13]
    Hiu, I.J., Nature New Biol.238, 241–242 (1972).PubMedGoogle Scholar
  14. [14]
    Chedid, L., Parant, M., Parant, E. and Gustafson, R.H., Proc. nat. Acad. Sci. Wash.69, 855–858 (1972).Google Scholar
  15. [15]
    Florentin, I., Bruley, M., and Belpomme, D., Cell Immun.17, 285–294 (1975).CrossRefGoogle Scholar
  16. [16]
    Bloom, B.R., and Bennett, B., Science153, 80–82 (1966).PubMedGoogle Scholar
  17. [17]
    Cleveland, R.P., Meltzer, M.S., and Zbar, B., J. nat. Cancer Inst.52, 1887–1895 (1974).PubMedGoogle Scholar
  18. [18]
    Hibbs, J.B., Lambert, L.H., and Remington, J.S., Proc. Soc. exp. Biol. Med.139, 1049–1052 (1972).PubMedGoogle Scholar
  19. [19]
    Keller, R., J. exp. Med.138, 625–644 (1973).CrossRefPubMedGoogle Scholar
  20. [20]
    Ghaffar, A., Cullen, R.T., Dunbar, N., and Woodruff, M.F.A., Br. J. Cancer29, 199–205 (1974).PubMedGoogle Scholar
  21. [21]
    Olivotto, M., and Bomford, R., Int. J. Cancer13, 478–488 (1974).PubMedGoogle Scholar
  22. [22]
    Keller, R., and Hess, M.W., Br. J. exp. Path.53, 570–577 (1972).Google Scholar

Copyright information

© Birkhäuser Verlag 1976

Authors and Affiliations

  • M. Bruley-Rosset
    • 1
  • I. Florentin
    • 1
  • G. Mathé
    • 1
  1. 1.Institut de Cancérologie et d'Immunogénétique (INSERM et Association Claude Bernard)Hôpital Paul BrousseVillejuifFrance

Personalised recommendations